July 20, 2017 1:22 PM ET

Pharmaceuticals

Company Overview of Napo Pharmaceuticals, Inc.

Company Overview

Napo Pharmaceuticals, Inc., a human health company, focuses on developing and commercializing novel gastrointestinal prescription products from plants. Its products include Mytesi, an FDA approved product for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. Napo Pharmaceuticals, Inc. was formerly known as PS Pharmaceuticals, Inc. The company was founded in 2001 and is based in San Francisco, California.

201 Mission Street

Suite 2375

San Francisco, CA 94105

United States

Founded in 2001

1 Employees

Phone:

844-722-8256

Key Executives for Napo Pharmaceuticals, Inc.

Founder, CEO & Executive Director
Age: 58
Chairman of Scientific Advisory Board & President
Age: 54
Chief Financial Officer
Age: 59
President of Napo India Private Limited
Age: 73
Senior Vice President of Global Access and Alliances
Compensation as of Fiscal Year 2017.

Napo Pharmaceuticals, Inc. Key Developments

Napo Pharmaceuticals, Inc. Presents at 2017 Marcum Microcap Conference, Jun-15-2017 03:30 PM

Napo Pharmaceuticals, Inc. Presents at 2017 Marcum Microcap Conference, Jun-15-2017 03:30 PM. Venue: The Grand Hyatt Hotel, New York, New York, United States.

Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. Announce Filing of Two Orphan Drug Designation Applications with FDA for Mytesi for Serious Unmet Medical Needs

Jaguar Animal Health, Inc. and Napo Pharmaceuticals, Inc. announced Napo’s filing of orphan drug designation applications with the U.S. Food & Drug Administration ‘FDA’ for Mytesi® for two areas of serious unmet medical needs: Congenital diarrheal disorders and diarrhea associated with short bowel syndrome. Napo’s Mytesi (crofelemer) product is approved by the U.S.FDA for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The Orphan Drug Act (ODA) provides for granting special status to a drug or biological product to treat a rare disease or condition upon request of a sponsor. This status is referred to as orphan designation or sometimes 'orphan status'. Orphan designation qualifies the sponsor of the drug for various development incentives, including tax credits for qualified clinical testing and relief of filing fees.

Napo Pharmaceuticals, Inc. Presents at Southern California Investment Forum, May-31-2017

Napo Pharmaceuticals, Inc. Presents at Southern California Investment Forum, May-31-2017 . Venue: Skylight Gardens Restaurant, Bar & Gallery, Los Angeles, United States. Speakers: Lisa A. Conte, Founder, Interim Chief Executive Officer and Executive Director.

Similar Private Companies By Industry

Company Name Region
1st Order Pharmaceuticals, Inc. United States
21st Century Animal Health United States
3 Buds' Organics LLC United States
4P Therapeutics LLC United States
60° Pharmaceuticals, LLC United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
January 3, 2017
--
Merger/Acquisition
October 6, 2016
Jaguar Animal Health, Inc.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
The Advertising Council, Inc. United States
Bertelsmann AG Europe
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Napo Pharmaceuticals, Inc., please visit www.napopharma.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.